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CC BY-NC-ND license (http://creativeBackground: The current consensus does not support the use of booster dose because of its
anamnestic response in almost all children 15 years after universal infant hepatitis B virus
(HBV) vaccination. However, in our clinical setting, numerous concerned parents request a
booster administration for their children. We aimed to provide the possible predictors of
booster response in adolescents before this booster administration.
Methods: This study comprised a series of cross-sectional serological surveys of HBV markers in
15-year-old individuals between 2008 and 2012. Data on serum hepatitis B surface antigen,
hepatitis B surface antibody (anti-HBs), and liver-function biomarkers in a total of 887 senior
high-school students were collected. There were two parts to this study: HBV seroepidemiol-
ogy and booster-response analysis to identify the possible response predictors and decay fac-
tors after the HBV booster administration.
Results: The overall anti-HBs and hepatitis B surface antigen seropositivity rates were 34.7%
and 0.7%, respectively, and the median anti-HBs titer was 3.3 mIU/mL. Six weeks after one
dose of recombinant HBV vaccine, the overall booster-response rate in the double-
seronegative recipients was 94% (471/501). Among the participants whose initial anti-HBs ti-
ters were undetectable or low, 72.4% (247/341) and 95.6% (153/160), respectively, reactivated
their anti-HBs titers  100 mIU/mL about 6 weeks after the booster administration. The likeli-
hood of postbooster anti-HBs titer reaching an adequate protective level increased with the
prebooster titer. The female participants had stronger anamnestic responses compared to
the male participants.of Pediatrics, 707, Section 3, Chung-Yang Road, Hualien 97002, Taiwan.
l.com (Y.-C. Chang).
to this work.
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Predicting booster response to HBV vaccine in 15-year-olds 303Figure 1 Flowchart of the stuConclusion: We found that the female participants and prebooster anti-HBs titers above the
detection limit of the immunoassay were good predictors of HBV booster response.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
The world’s first nationwide hepatitis B virus (HBV) infant-
vaccination program was launched in Taiwan in July 1984,
starting with newborns to highly infectious mothers, and
expanding to all newborns in July 1986.1 Prior to July 1992,
infants were given four doses (5 mg/dose) of plasma-derived
vaccine (Hevac B; Pasteur-Me´rieux, Lyon, France, or its
equivalent derivative) at birth, and at 1, 2, and 12 months
of age. After July 1992, three doses of recombinant vaccine
[5 mg/dose of Recombivax (Merck, Merk Sharp & Dohme,
Rahway, NJ, USA) or 20 mg/dose of Engerix (SmithKline
Beecham, Rixensart, Belgium)] were administered before
the age of 1 week, 1 month, and 6 months.2 Based on
vaccine-efficacy studies, the protective cutoff level of an-
tibodies against the hepatitis B surface antigen (HBsAg) was
set at  10 mIU/mL.3 Among the children who initially
responded to the primary three-dose vaccination series,
15e50% demonstrated a low or undetectable hepatitis B
surface antibody (anti-HBs) level 5e15 years after primary
vaccination.4 A large-scale study provided evidence that an
anamnestic anti-HBs response was absent in 10.1% of 15- to
18-year-old individuals in Taiwan, a country that had high
endemicity of HBV.5 The current guidelines from the Taiwan
Advisory Committee on Immunization Practices state that
individuals may receive a booster dose if they havedy design. anti-HBs Z hepatitinegative anti-HBs antibodies and belong to high-risk groups
(i.e., sexual/household contacts to infected people,
hemodialysed, organ-transplant recipients, immunocom-
promised patients, intravenous drug users, participants in
high-risk sexual activity, or health-care workers). Clinically,
we are still encountering numerous concerned parents who
request booster administrations for their children who do
not belong to any high-risk group. We aimed to provide the
possible predictors of booster response in adolescents
before booster administration.
In this report, we describe the two parts of our study: HBV
seroepidemiology and booster analysis, including immuno-
genicity response to booster, and the survey of the possible
predictors of HBV booster response at 15 years of age.
2. Methods
2.1. Study population
This was a retrospective cross-sectional study between
2008 and 2012 composed of the serological surveys of HBV
markers in newly enrolled students of the Tzu Chi senior
high school (birth cohort 1993e1997) in Eastern Taiwan. A
flowchart indicating our study design is depicted in
Figure 1. An approval certificate for this study was issued bys B surface antibody; HBsAg Z hepatitis B surface antigen.
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Buddhist Tzu Chi Medical Foundation (Research Ethics
Committee (REC) number: IRB101e125). A total of 906
students were initially recruited in our study, and we
excluded those without the records of paired HBV markers
(anti-HBs/HBsAg), as well as those without complete health
examinations, leaving a total of 887 participants in the
epidemiological study. The vaccination cards of each
participant were not reviewed individually in our study, and
the estimated coverage rates of complete HBV vaccination
in our participants were comparable with the participants
of the same birth cohort (1993e1997) in Taiwan. Based on
the statistical data from the Center for Disease Control in
Taiwan, Ni et al6 reported that the coverage rates of
complete HBV vaccination were 91.1e93.5% with birth
cohort 1993e1997 in Table 1 of their study. A written con-
sent was obtained from the students’ parents or guardians
upon school enrollment using forms provided by the Hualien
County Government Education Bureau. The consent form
informed parents/guardians that these examinations were
nonintrusive with minimal risk, and the students or par-
ents/guardians were free to withdraw from any examina-
tion parameter at any time.
2.2. Epidemiological study
Blood samples were collected from each student as a part
of their health examination during the first semester of
their senior high school. The rates of anti-HBs and HBsAg
seropositivity, anti-HBs serum titers, and liver-function
biomarkers were collected. The rates of anti-HBs and
HBsAg seropositivity along with other demographic char-
acteristics, such as sex and age and the median titers of
anti-HBs, were also compared. We divided our study par-
ticipants into two groups owing to the fact that different
serologic test systems had been used to determine the anti-
HBs titers [i.e., the VITROS ECiQ immunoassay (Ortho
Clinical Diagnostics, Raritan, NJ, USA) during the school
years that began between 2008 and 2010, and the Abbott
Laboratories ARCHITECT (North Chicago, IL, USA) anti-HBs
immunoassay during the school years that began between
2011 and 2012]. These two immunoassay systems had
different detection limits. Therefore, we grouped our
participants for comparison based on the assay methods
used in different school years into group 2008e2010 and
group 2011e2012. No data for hepatitis B core antibody
were available within our database. Therefore, the preva-
lence rates of natural infection could not be estimated in
our study.
2.3. Booster analysis
2.3.1. Response rate in booster recipients at 15 years of
age
In our database, individuals demonstrating double sero-
negativity for anti-HBs and HBsAg were advised by the
school nurses to receive one booster dose of recombinant
HBV vaccine (20 mg/dose) based on the guidelines from the
Taiwan Advisory Committee on Immunization Practices. If
written consent was obtained from the student’s parent or
guardian, this booster dose was to be administered on thesame day in their school clinic under the supervision of the
family physician. Postbooster blood sampling for anti-HBs
titers was also performed on the same day in the school
clinic an average of 6 weeks after their booster date. The
response rate to this single booster dose of HBV vaccine was
defined as the proportion of booster recipients whose
postbooster anti-HBs titer was  10 mIU/mL. For the
evaluation of any possible predictors of booster response, a
logistic-regression model was used for statistical analysis
and the odds ratio (OR) was calculated. Sex and prebooster
anti-HBs titers were both used as variables in our analysis.
2.3.2. Longitudinal study
After tracking our senior high-school participants by their
birth cohort in our university database, we found that some
of our previous booster recipients had studied in our senior
high school prior to attending our university. We decided to
trace the pattern of seroconversion and postbooster
changes over a 3-year interval in the booster recipients
from the birth cohort 1993e1994 (school year 2008e2009).
We aimed to identify the factors affecting the decay rate of
booster recipients by comparing the 6-week and 3-year
postbooster anti-HBs titers among individuals with different
prebooster titers and sex.
2.4. Serologic testing
All the quantifications of seromarkers of HBV infection were
performed using enzyme immunoassays (data prior to
August 31, 2011, VITROS ECiQ Immunodiagnostics System;
data after September 1, 2011, Abbott Laboratories). In the
VITROS system, the values of anti-HBs below 4.23 mIU/mL
would be interpreted as undetectable in the school years
2008e2010. However, the value of anti-HBs below 1 mIU/
mL would be interpreted as undetectable in the school
years 2011e2012 by the Abbott system. The protective
level of anti-HBs was defined as  10 mIU/mL based on the
World Health Organization criteria.3 Participants who were
positive for HBsAg were assumed to be HBV carriers.7
Elevated aspartate transaminase (AST) and alanine trans-
aminase (ALT) were defined as > 40 U/L in our study.
2.5. Statistical analysis
A Chi-square test was performed to identify the differences
in anti-HBs and HBsAg seropositivity rates, and the median
titers of anti-HBs between different school years, sexes,
and other subgroups. Statistically significant differences
were defined as p < 0.05. All the statistical analyses were
performed using the SPSS software (version 17.0; SPSS Inc.,
Chicago, IL, USA). For evaluating any possible predictors of
booster response, a logistic-regression model was used for
statistical analysis, and the adjusted OR was calculated.
3. Results
3.1. Part I: Epidemiological study
The study participants of this epidemiological survey con-
sisted of 887 15-year-old individuals (462 males and 425
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national infant HBV vaccination era of Taiwan, and had
received the recombinant HBV vaccines during their in-
fancy. The overall anti-HBs and HBsAg seropositivity rates in
our students were 34.7% and 0.7%, respectively. Table 1
shows a statistically significant difference in the seroposi-
tivity rate and median titers of anti-HBs between the
different school-year groups (group 2008e2010 and group
2011e2012, p < 0.001). We also compared the seropreva-
lence of HBV markers between sexes for all participants,
but there were no statistically significant differences.
Elevated (> 40 U/L) AST and ALT were more prominent in
male participants with statistical significance (p Z 0.022
and p < 0.001, respectively), but none of the six HBV car-
riers in our study had elevated liver-function markers (AST
and ALT).
3.2. Part II: Booster analysis3.2.1. Distribution of prebooster anti-HBs titers in HBV
booster recipients in each school year
Of these 579 individuals with double seronegativity of anti-
HBs and HBsAg, 501 (86.5%) participated in this part of ourTable 1 Demographics data (N Z 887).
Item Year
2008e2010
(n Z 517)
2011e2012
(n Z 370)
p
Sex 0.454
Male, n (%) 275 (53.2) 187 (50.5)
Female, n (%) 242 (46.8) 183 (49.5)
Age, mean  SD (y) 15.5  0.4 15.5  0.4 0.190
Anti-HBs <0.001*
Anti-HBs (þ),
n (%, 95% CI)
214 (41.4,
37.2e45.6)
94 (25.4,
21.0e29.8)
Anti-HBs (),
n (%, 95% CI)
303 (58.6,
54.4e62.8)
276 (74.6,
70.2e79.0)
Anti-HBs titer,
median
4.8 1.9 <0.001*
HBsAg 0.410
HBsAg (þ),
n (%, 95% CI)
5 (1.0, 0.1e1.9) 1 (0.3, 0.0e0.9)
HBsAg (),
n (%, 95% CI)
512 (99.0,
98.1e99.9)
369 (99.7,
99.1e100.0)
TCH 150.5  27.5 142.2  27.0 <0.001*
AST 20.5  6.3 18.1  9.6 <0.001*
AST 0.912
 40, n (%) 511 (98.8) 366 (98.9)
> 40, n (%) 6 (1.2) 4 (1.1)
ALT 16.3  12.7 17.9  12.4 0.074
ALT 0.772
 40, n (%) 498 (96.3) 355 (95.9)
> 40, n (%) 19 (3.7) 15 (4.1)
Data are presented as mean  standard deviation, or n and percenta
*A value of p < 0.05 was considered statistically significant after the
ALT Z alanine transaminase; anti-HBs Z hepatitis B surface antib
HBsAg Z hepatitis B surface antigen; NA Z not available; SD Z stanbooster study. We further categorized all the booster re-
cipients based on their prebooster anti-HBs titers into an
“undetectable” group, whose values were below the level
of detection limit (< 4.3 mIU/mL for the 2008e2010 school
years; < 1 mIU/mL for the 2011e2012 school year), and
“low titer” group, whose values were between the detec-
tion limit and 10 mIU/mL. Among these 501 booster re-
cipients, 68.1% (341/501) had prebooster anti-HBs titers
that placed them in the “undetectable” group, and 31.9%
(160/501) belonged to the “low titer” group.
3.2.2. Correlation of prebooster and postbooster anti-
HBs titers
The 501 individuals demonstrating seronegativity for both
anti-HBs and HBsAg received one booster dose of recom-
binant HBV vaccine (20 mg/dose). As indicated in Table 2,
the distributions of prebooster and postbooster titers by sex
were not significantly different. The demographic data of
booster recipients show that the male individuals had
higher values of AST and ALT (p < 0.001); furthermore, a
higher proportion of individuals with elevated AST/ALT was
noted among the male participants with p < 0.030 and
p < 0.001, respectively. The overall response rate among
booster recipients with postbooster anti-HBs titers Sex Total (n Z 887)
Male
(n Z 462)
Female
(n Z 425)
p
NA
462 (100.0) 0 (0.0) 462 (52.1)
0 (0.0) 425 (100.0) 425 (47.9)
15.5  0.4 15.5  0.4 0.271 15.5  0.4
0.364
154 (33.3,
29.0e37.6)
154 (36.2,
31.6e40.8)
308 (34.7,
31.6e37.8)
308 (66.7,
62.4e71.0)
271 (63.8,
59.2e68.4)
579 (65.3,
62.2e68.4)
3.0 3.6 0.839 3.3
0.918
3 (0.6, 0.0e1.3) 3 (0.7, 0.0e1.5) 6 (0.7,
0.2e1.2)
459 (99.4,
98.7e100.0)
422 (99.3,
98.5e100.0)
881 (99.3,
98.8e99.8)
143.2  28.5 151.3  25.9 <0.001* 147.0  27.6
21.4  9.9 17.3  4.0 <0.001* 19.5  7.9
0.022*
453 (98.1) 424 (99.8) 877 (98.9)
9 (1.9) 1 (0.2) 10 (1.1)
20.6  15.8 13.0  5.4 <0.001* 17.0  12.6
<0.001*
430 (93.1) 423 (99.5) 853 (96.2)
32 (6.9) 2 (0.5) 34 (3.8)
ge.
test.
ody; AST Z aspartate transaminase; CI Z confidence interval;
dard deviation; TCH Z total cholesterol.
Table 2 Comparison between men and women among booster recipients (N Z 501).
Item Male Female Total p
N 255 246 501 NA
Age, mean  SD (y) 15.5  0.3 15.5  0.4 15.5  0.4 0.175
Prebooster anti-HBs d d d 0.495
Undetectable 170 (66.7) 171 (69.5) 341 (68.1)
Low titer 85 (33.3) 75 (30.5) 160 (31.9)
Median titer (IQR) 1.4 (2.81) 0.8 (2.95) 1 (2.91) 0.246
Postbooster anti-HBs d d d 0.122
<10 20 (7.8) 10 (4.1) 30 (6.0)
10e99 41 (16.1) 30 (12.2) 71 (14.2)
100e999 109 (42.7) 108 (43.9) 217 (43.3)
1000 85 (33.3) 98 (39.8) 183 (36.5)
Median titer (IQR) 558.6 (891.0) 673.5 (808.5) 570 (851.5) 0.066
TCH 144.4  27.5 150.3  25.4 147.3  26.6 0.013*
AST 21.3  7.8 17.0  3.6 19.2  6.5 <0.001*
AST d d d 0.030*
40, n (%) 249 (97.6) 246 (100.0) 495 (98.8)
>40, n (%) 6 (2.4) 0 (0.0) 6 (1.2)
ALT 22.0  17.6 13.1  4.7 17.6  13.7 <0.001*
ALT d d d <0.001*
40, n (%) 231 (90.6) 246 (100.0) 477 (95.2)
>40, n (%) 24 (9.4) 0 (0.0) 24 (4.8)
Data are presented as mean  standard deviation, or n and percentage.
*A value of p < 0.05 was considered statistically significant after the test.
ALT Z alanine transaminase; anti-HBs Z hepatitis B surface antibody; AST Z aspartate transaminase; IQR Z interquartile range
25e75%; NA Z not available; SD Z standard deviation; TCH Z total cholesterol.
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administration. The median anti-HBs titers in recipients
before and after booster administration were 1 mIU/mL
(IQR 2.91) and 570 mIU/mL (IQR 851.5), respectively. IQR
stands for the “interquartile range.” We also observed a
statistical trend in female individuals who had higher me-
dian titers of anti-HBs after booster administration
(p Z 0.066).
In Figure 2, the bubble plot shows the change in anti-HBs
titer level before and after the HBV booster administration.
Among the 341 participants in the “undetectable” group,
44.6% (152/341) attained postbooster titers ranging from
100 mIU/mL to < 1000 mIU/mL, and 27.9% (95/341) had
postbooster titers  1000 mIU/mL. For these 160 partici-
pants in the “low titer” group, 40.6% (65/160) had the
postbooster titers ranging from 100 mIU/mL to < 1000 mIU/
mL, and 55% (88/160) had postbooster titers  1000 mIU/
mL. All 6% (30/501) of the recipients who failed to reac-
tivate their immune memory belonged to the “undetect-
able” group before the booster dose.
In Table 3, the comparison between sexes shows that,
compared to the male participants, the female participants
had a higher likelihood, as indicated by the adjusted
multivariate OR 2.04 [95% CI 0.92e4.52], of achieving post-
booster anti-HBs titers  10 mIU/mL; if the target value of
postbooster titers was set as 100 mIU/mL, the adjusted OR
of female participants became 1.72 (95% CI 1.08e2.73).
When the prebooster titer was used as variant for the
logistic-regression analysis, the “low titer” group was more
likely to achieve a target anti-HBs titer  100 mIU/mL
compared to the “undetectable” group, as reflected by the
adjusted multivariate OR 7.51 (95% CI 3.34e16.91).3.2.3. Longitudinal study
In our previous study in 2014,8 we studied 38 18-year-old
individuals (birth cohort 1993e1994) who had studied in our
senior high school prior to attending our university. Among
the 25 booster recipients, 96% (24/25) regained protective
levels of anti-HBs with a median anti-HBs titer of 353 mIU/
mL after one booster dose of HBV vaccine at age 15.
However, among the 24 recipients who were anti-HBs
seropositive at 6 weeks after booster administration,
seven individuals (29.2%) had lost their anti-HBs seroposi-
tivity again within 3 years. During this interval, the median
anti-HBs titer decayed from 353.0 mIU/mL to 21.1 mIU/mL
(94% reduction). The percentages of decay rate among fe-
male and male individuals within a 3-year interval were
89.2  12.2 and 76.0  28.9, respectively (pZ 0.159). The
percentages of decay rate among the “undetectable” and
“low titer” groups were 82.5  24.1 and 83.5  10.3,
respectively (pZ 0.942), as shown in Table S1. There were
no statistically significant differences due to the small
sample size in this longitudinal study.4. Discussion
In previous studies conducted in Taiwan, the anti-HBs
seropositivity rate declined from 99% at 1 year of age to
83% at 5 years of age,9 and further dropped to 37% at 15e17
years of age.10 In a 2004 survey, Ni et al6 showed that the
anti-hepatitis B core seropositivity rate was low (1%) in
children less than 15 years of age. In the report by Lin
et al,11 the age of the participants was very close to the one
in this study (16 and 15.5 years); the anti-HBs and HBsAg
Figure 2 Change in hepatitis B surface antibody titer level before and after the hepatitis B virus booster administration. anti-
HBs Z hepatitis B surface antibody.
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(448/679) and 0.7% (5/679), which were comparable with
the seropositivity rates of anti-HBs (34.7%) and HBsAg
(0.7%) in our study.Table 3 Logistic-regression analysis for factors associated with
antibody titer (N Z 501).
Postbooster anti-HBs titer > 10
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Sex d d d d
Male 1 NA 1 N
Female 2.01 (0.92e4.38) 0.080 2.04 (0.92e4.52) 0
Period d d d d
2008e2010 1 NA 1 N
2011e2012 4.98 (1.87e13.23) <0.001* 3.05 (1.13e8.22) 0
Prebooster
anti-HBs titer
d d d d
Undetectable 1 NA 1 N
Low titer 1.56E8 (NA) 0.995 1.09E8 (NA) 0
Data are presented as odds ratio (95% CI).
*A value of p < 0.05 was considered statistically significant after the
anti-HBs Z hepatitis B surface antibody; OR Z odds ratio; CI Z confiBased on data from previous studies, different types of
hepatitis B vaccines, doses, and brands, as well as the
timing of primary vaccination, can all influence the
persistence of anti-HBs titers.12 Therefore, only those whobooster response by different postbooster hepatitis B surface
Postbooster anti-HBs titer > 100
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
d d d d
A 1 NA 1 NA
.080 1.62 (1.04e2.53) 0.034* 1.72 (1.08e2.73) 0.023*
d d d d
A 1 NA 1 NA
.027* 2.34 (1.47e3.71) <0.001* 1.53 (0.94e2.50) 0.089
d d d d
A 1 NA 1 NA
.995 8.32 (3.76e18.40) <0.001* 7.51 (3.34e16.91) <0.001*
test.
dence interval; NA Z not available.
308 Y.-S. Chen et alreceived recombinant HBV vaccine were selected in our
study to avoid the possible interference of different vac-
cine types given in infancy. Our results found that the
participants in 2008e2010 had higher seropositive rates of
anti-HBs and median anti-HBs titers than those of
2011e2012 (41.4% vs. 25.4%, p < 0.001). However, indi-
vidual vaccination cards and background information, such
as household contact, were not provided in our database,
so further study should be conducted to identify the
possible reasons of this significant difference. Neverthe-
less, there were no statistically significant differences of
seropositive rate of HBV markers between sexes for all
participants in this study.
Among the 501 individuals who were our booster re-
cipients, the booster-response rate was 94% (471/501) after
one booster dose of recombinant HBV vaccine (20 mg/dose),
which demonstrated the integrity of anamnestic response
in our 15-year-old recipients. Lin et al11 showed that the
booster-response rate to one dose of recombinant HBV
vaccine was 95.9% (326/340) in 16-year-old participants
who received recombinant HBV vaccine during their
neonatal immunization.
Jan et al13 showed that, when immune memory was
present, the anti-HBs responses could be induced as early
as 1 week following a booster, and such responders were
likely to have protective titers after a single dose. In their
study, almost all early responders (anti-HBs  10 mIU/mL at
7e10 days after a booster dose) had high anti-HBs titers (
100 mIU/mL) after 1 month.13 Defining the presence of HBV
vaccine immune memory could be problematic, because
the production of anti-HBs titers  10 mIU/mL 1 month
after booster vaccination may result from either a primary
immune response or anamnestic response. Therefore, the
group of individuals who mounted low-level anti-HBs
(10e99 mIU/mL) responses after one dose of HBV vaccine
may have manifested an anamnestic response or a primary
response after the loss of immune memory.13
As illustrated in Figure 2, our study showed that 72.5%
(247/341) of the participants in the “undetectable” group
reactivated their anti-HBs titers to  100 mIU/mL about 6
weeks after one booster dose of HBV vaccine. In the “low
titer” group, 95.6% of the participants regained postbooster
titers of anti-HBs above 100 mIU/mL within the same time
interval. The likelihood of postbooster titer reaching an
adequate protective level increased with the prebooster
anti-HBs titers, up to postbooster anti-HBs titers as high as
 100 mIU/mL.
Sex difference was another factor found to affect the
booster response in our study. We found that the female
participants had a significantly stronger booster response
compared with the male individuals (adjusted OR 1.72). It
was previously reported that, in humans, female individuals
usually express higher levels of antibodies and antibody-
stimulating Th2 cytokines.14,15 Females also had a stronger
immunogenic response to HBV vaccine with higher anti-HBs
seropositivity and a reduced chance for hepatitis B
infection.16e18 However, we did not detect significant sex
differences in anti-HBs titers and HBsAg seropositivity rates
in this study, although we did observe a greater proportion
of male individuals with elevated AST/ALT. In this study,
the female individuals seem to correlate with a trend of
faster anti-HBs decay.In conclusion, we found that 91.2% of those recipients in
the “undetectable” group were able to reactivate their
immune memory to achieve protective anti-HBs titers after
one booster dose of HBV vaccine. The likelihood of post-
booster titer reaching an adequate protective level
increased with the prebooster anti-HBs titers. Female in-
dividuals had stronger anamnestic response than male
individuals.
There were major limitations to our study. First, this
retrospective cross-sectional study, including the design
and records analysis, was conducted without reviewing the
vaccination records of the participants. Second, we could
not verify whether the participants had HBV booster vac-
cinations prior to our booster study. Third, the types of
recombinant HBV vaccine (e.g., 5 mg/dose of Recombivax or
20 mg/dose of Engerix) used for the neonatal immunization
of each booster recipient could not be identified; there-
fore, the possible dosage effects of HBV vaccine on our
booster response could not be evaluated.
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